+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Zevalin"

Betalutin - Product Thumbnail Image

Betalutin

  • Report
  • January 2019
  • 17 Pages
  • Global
From
NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026 - Product Thumbnail Image

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • Drug Pipelines
  • January 2019
  • 510 Pages
  • Global
From
Zevalin - Product Thumbnail Image

Zevalin

  • Report
  • January 2019
  • 17 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Zevalin is a type of leukemia drug used to treat certain types of non-Hodgkin's lymphoma. It is a monoclonal antibody-based therapy that works by targeting and killing cancer cells. Zevalin is administered intravenously and is used in combination with other chemotherapy drugs. It is approved for use in patients who have not responded to other treatments or who have relapsed after initial treatment. The Zevalin market is a rapidly growing segment of the global oncology market. It is expected to experience strong growth in the coming years due to the increasing prevalence of non-Hodgkin's lymphoma and the increasing demand for targeted therapies. Some of the major companies in the Zevalin market include Pfizer, Merck, Novartis, and Bayer. These companies are actively involved in the development and commercialization of Zevalin and other targeted therapies for the treatment of non-Hodgkin's lymphoma. Show Less Read more